Search

Enitan A Bababunmi

from Kendall Park, NJ
Age ~84
Get Report
Also known as:
Enitan Dr Bababunmi, Enitan I, Enitan L
Related to:
Josephine A Bababunmi, 82
Connected to:
Robert J Babacz, 67Eliyahu R Babad, 43Harry Babad, 89Pedram Babadi, 53Sara M Babadi, 44Inessa Babadzhanova, 42Jacob Babadzhanov, 43Hossein Babaee, 38Aliakbar Babaei, 43Vahid Babaei, 39

Enitan Bababunmi Phones & Addresses

  • Kendall Park, NJ
  • Newark, DE
  • New York, NY
  • Norcross, GA
  • Newark, NY
  • Clarksville, TN
  • Falls Church, VA

Publications

Us Patents

Formulation And Method For Treating Skeletal Muscle Degeneration Caused By Malnutrition And Disease

View page
US Patent:
6887499, May 3, 2005
Filed:
Sep 24, 2002
Appl. No.:
10/252525
Inventors:
Enitan A. Bababunmi - Norcross GA, US
International Classification:
A61K035/78
US Classification:
424757, 424725, 426629, 426590, 514 27, 514456
Abstract:
A formulation is provided for the treatment of the adverse affects of skeletal muscle degenerative diseases prevalent in humans in developing countries. The formulation typically includes a first component including at least one of jasmone, a jasmonate, jasmonic acid, oxo-phytodienoic acid, and a second component including at least one of an antioxidant and carnitine. Additionally, soy milk may be utilized as a delivery vehicle for the formulation for oral ingestion by a subject. The formulation is designed to replenish energy levels in disease infected muscle cells, reinstate calcium homeostasis within the muscle cells, and reduce the activity of oxidizing free radical reactions typically caused by muscle degenerative diseases.

Formulation And Method For Treating Skeletal Muscle Degeneration Caused By Malnutrition And Disease

View page
US Patent:
20020006911, Jan 17, 2002
Filed:
May 22, 2001
Appl. No.:
09/863069
Inventors:
Enitan Bababunmi - Norcross GA, US
International Classification:
A61K035/78
A61K031/195
A61K031/215
US Classification:
514/027000, 424/757000, 514/456000, 514/529000, 514/561000
Abstract:
A formulation is provided for the treatment of the adverse affects of skeletal muscle degenerative diseases prevalent in humans in developing countries. The formulation typically includes jasmone and at least one of an antioxidant and carnitine. Additionally, soy milk may be utilized as a delivery vehicle for the formulation for oral ingestion by a subject. The formulation is designed to replenish energy levels in disease infected muscle cells, reinstate calcium homeostasis within the muscle cells, and reduce the activity of oxidizing free radical reactions typically caused by muscle degenerative diseases.
Control profile
Enitan A Bababunmi from Kendall Park, NJ, age ~84 Get Report